VRDN · NASDAQ · STOCK
Viridian Therapeutics, Inc.
$23.00
52W $13.18 – $34.29
64/100
$2.60B
-6.3
0.94
Is VRDN Bullish or Bearish?
Bullish.
Innellis AI committee rates Viridian Therapeutics, Inc. (VRDN) Buy with a composite score of 64/100
, based on 6 analysts with 50% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +10.77 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -9.23 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull & Bear Case
Bull Case
- Revenue growing 23220.3% YoY -- genuine top-line momentum — Growth
- MACD histogram positive -- bullish momentum — Technical
- Low leverage (debt-to-equity 0.12) -- balance sheet can absorb a shock — Risk
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- News sentiment is positive (+0.50 across 4 articles, 14d) — News
Bear Case
- Price-to-book of 4.1x prices in significant intangible value — Value
- ROE of only -61.4% -- cheap may mean cheap for a reason — Value
- RSI at 74 is in overbought territory — Technical
- Bollinger bandwidth of 33.7% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
64/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 21%
of 192 Healthcare peers
Value Analyst
neutral
43
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 4.1x prices in significant intangible value
Growth Analyst
bullish
85
/ 100 · Low confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 23220.3% YoY -- genuine top-line momentum
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− RSI at 74 is in overbought territory
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.12) -- balance sheet can absorb a shock
− Bollinger bandwidth of 33.7% signals elevated volatility
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
74
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.50 across 4 articles, 14d)
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
74.5
Overbought
MACD Histogram
0.354
Bullish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$15.71
Resistance
$34.25
Bollinger %B
0.93
Inside Bands
Price vs Moving Averages
EMA 9
$21.78
Above
EMA 21
$20.55
Above
EMA 50
$19.42
Above
EMA 200
$20.90
Above
Fundamental Analysis
Valuation
88
Profitability
25
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-6.3×
P/B Ratio
3.74×
PEG Ratio
-1.17
Dividend Yield
0.00%
52W High
$34.29
52W Low
$13.18
Quality & Growth
ROE
-4744.1%
ROA
-3809.1%
Gross Margin
9938.0%
Operating Margin
—
Revenue Growth YoY
—
Debt / Equity
0.37
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -6.3 (inexpensive relative to a 15-40x range); Price-to-book of 3.7x; PEG ratio of -1.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -47.4%; Return on assets of -38.1%; Net margin of -544.1%; Gross margin of 99.4%; Current ratio of 16.95 (healthy short-term liquidity); Debt-to-equity of 0.37; Free cash flow per share is negative (-3.11); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full VRDN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →